NDAORALTABLET
Approved
Sep 2015
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
6
Data completeness
7/8 — Comprehensive
LONSURF (trifluridine and tipiracil) by Taiho Oncology is nucleic acid synthesis inhibitors [moa]. Approved for nucleoside analog antiviral [epc]. First approved in 2015.
Drug data last refreshed 2d ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LONSURF is an oral nucleoside analog antiviral combining trifluridine and tipiracil that inhibits nucleic acid synthesis. Approved in 2015, it is used to treat advanced cancers where nucleoside metabolism is a therapeutic target. The tipiracil component enhances trifluridine bioavailability by inhibiting its degradation.
$0.176BPart D
Peak10.6 years to LOELONSURF is in peak commercial phase with $176M in Part D spending (2023), suggesting a stable mid-size sales force focused on oncology specialists and sustained medical affairs engagement.
Mechanism of Action
Nucleic Acid Synthesis Inhibitors
Pharmacologic Class:
Nucleoside Analog Antiviral
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (6)
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
Started May 2026
700 enrolled
Colorectal Cancer
Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced (PDAC)
Started Sep 2019
14 enrolled
Pancreatic CancerPancreatic Ductal Adenocarcinoma
Bioequivalence Study of Trifluridine and Tipiracil Tablets in Colorectal Cancer Patients
Started May 2019
64 enrolled
Colorectal Cancer
First-in-human Study of CA102N Monotherapy and CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors
Started Apr 2019
37 enrolled
Advanced or Metastatic Solid TumorsAdvanced or Metastatic Colorectal Cancer (mCRC)
A Phase II Study of Lonsurf (TAS-102) in Metastatic Platinum and Checkpoint Inhibitor-resistant Bladder Cancer
Started Jan 2019
22 enrolled
Bladder Cancer
Worked on LONSURF at Taiho Oncology? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.